Cargando…

Targeting TROY-mediated P85a/AKT/TBX3 signaling attenuates tumor stemness and elevates treatment response in hepatocellular carcinoma

BACKGROUND: Previous in vitro hepatocyte differentiation model showed that TROY was specifically expressed in liver progenitor cells and a small proportion of hepatocellular carcinoma cells, suggesting that TROY may participate in hepatocellular carcinoma (HCC) stemness regulation. Here, we aim to i...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Beilei, Fang, Xiaona, Kwong, Dora Lai-Wan, Zhang, Yu, Verhoeft, Krista, Gong, Lanqi, Zhang, Baifeng, Chen, Jie, Yu, Qianqian, Luo, Jie, Tang, Ying, Huang, Tuxiong, Ling, Fei, Fu, Li, Yan, Qian, Guan, Xin-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131684/
https://www.ncbi.nlm.nih.gov/pubmed/35610614
http://dx.doi.org/10.1186/s13046-022-02401-6
_version_ 1784713225396289536
author Liu, Beilei
Fang, Xiaona
Kwong, Dora Lai-Wan
Zhang, Yu
Verhoeft, Krista
Gong, Lanqi
Zhang, Baifeng
Chen, Jie
Yu, Qianqian
Luo, Jie
Tang, Ying
Huang, Tuxiong
Ling, Fei
Fu, Li
Yan, Qian
Guan, Xin-Yuan
author_facet Liu, Beilei
Fang, Xiaona
Kwong, Dora Lai-Wan
Zhang, Yu
Verhoeft, Krista
Gong, Lanqi
Zhang, Baifeng
Chen, Jie
Yu, Qianqian
Luo, Jie
Tang, Ying
Huang, Tuxiong
Ling, Fei
Fu, Li
Yan, Qian
Guan, Xin-Yuan
author_sort Liu, Beilei
collection PubMed
description BACKGROUND: Previous in vitro hepatocyte differentiation model showed that TROY was specifically expressed in liver progenitor cells and a small proportion of hepatocellular carcinoma cells, suggesting that TROY may participate in hepatocellular carcinoma (HCC) stemness regulation. Here, we aim to investigate the role and mechanism of TROY in HCC pathogenesis. METHOD: Bioinformatics analysis of the TCGA dataset has been used to identify the function and mechanism of TROY. Spheroid, apoptosis, and ALDH assay were performed to evaluate the stemness functions. Validation of the downstream pathway was based on Western blot, co-immunoprecipitation, and double immunofluorescence. RESULTS: HCC tissue microarray study found that a high frequency of TROY-positive cells was detected in 53/130 (40.8%) of HCC cases, which was significantly associated with poor prognosis and tumor metastasis. Functional studies revealed that TROY could promote self-renewal, drug resistance, tumorigenicity, and metastasis of HCC cells. Mechanism study found that TROY could interact with PI3K subunit p85α, inducing its polyubiquitylation and degradation. The degradation of p85α subsequently activate PI3K/AKT/TBX3 signaling and upregulated pluripotent genes expression including SOX2, NANOG, and OCT4, and promoted EMT in HCC cells. Interestingly, immune cell infiltration analysis found that upregulation of TROY in HCC tissues was induced by TGF-β1 secreted from CAFs. PI3K inhibitor wortmannin could effectively impair tumor stemness to sorafenib. CONCLUSION: We demonstrated that TROY is an HCC CSC marker and plays an important role in HCC stemness regulation. Targeting TROY-positive CSCs with PI3K inhibitor wortmannin combined with chemo- or targeted drugs might be a novel therapeutic strategy for HCC patients. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-022-02401-6.
format Online
Article
Text
id pubmed-9131684
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-91316842022-05-26 Targeting TROY-mediated P85a/AKT/TBX3 signaling attenuates tumor stemness and elevates treatment response in hepatocellular carcinoma Liu, Beilei Fang, Xiaona Kwong, Dora Lai-Wan Zhang, Yu Verhoeft, Krista Gong, Lanqi Zhang, Baifeng Chen, Jie Yu, Qianqian Luo, Jie Tang, Ying Huang, Tuxiong Ling, Fei Fu, Li Yan, Qian Guan, Xin-Yuan J Exp Clin Cancer Res Research BACKGROUND: Previous in vitro hepatocyte differentiation model showed that TROY was specifically expressed in liver progenitor cells and a small proportion of hepatocellular carcinoma cells, suggesting that TROY may participate in hepatocellular carcinoma (HCC) stemness regulation. Here, we aim to investigate the role and mechanism of TROY in HCC pathogenesis. METHOD: Bioinformatics analysis of the TCGA dataset has been used to identify the function and mechanism of TROY. Spheroid, apoptosis, and ALDH assay were performed to evaluate the stemness functions. Validation of the downstream pathway was based on Western blot, co-immunoprecipitation, and double immunofluorescence. RESULTS: HCC tissue microarray study found that a high frequency of TROY-positive cells was detected in 53/130 (40.8%) of HCC cases, which was significantly associated with poor prognosis and tumor metastasis. Functional studies revealed that TROY could promote self-renewal, drug resistance, tumorigenicity, and metastasis of HCC cells. Mechanism study found that TROY could interact with PI3K subunit p85α, inducing its polyubiquitylation and degradation. The degradation of p85α subsequently activate PI3K/AKT/TBX3 signaling and upregulated pluripotent genes expression including SOX2, NANOG, and OCT4, and promoted EMT in HCC cells. Interestingly, immune cell infiltration analysis found that upregulation of TROY in HCC tissues was induced by TGF-β1 secreted from CAFs. PI3K inhibitor wortmannin could effectively impair tumor stemness to sorafenib. CONCLUSION: We demonstrated that TROY is an HCC CSC marker and plays an important role in HCC stemness regulation. Targeting TROY-positive CSCs with PI3K inhibitor wortmannin combined with chemo- or targeted drugs might be a novel therapeutic strategy for HCC patients. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-022-02401-6. BioMed Central 2022-05-25 /pmc/articles/PMC9131684/ /pubmed/35610614 http://dx.doi.org/10.1186/s13046-022-02401-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Liu, Beilei
Fang, Xiaona
Kwong, Dora Lai-Wan
Zhang, Yu
Verhoeft, Krista
Gong, Lanqi
Zhang, Baifeng
Chen, Jie
Yu, Qianqian
Luo, Jie
Tang, Ying
Huang, Tuxiong
Ling, Fei
Fu, Li
Yan, Qian
Guan, Xin-Yuan
Targeting TROY-mediated P85a/AKT/TBX3 signaling attenuates tumor stemness and elevates treatment response in hepatocellular carcinoma
title Targeting TROY-mediated P85a/AKT/TBX3 signaling attenuates tumor stemness and elevates treatment response in hepatocellular carcinoma
title_full Targeting TROY-mediated P85a/AKT/TBX3 signaling attenuates tumor stemness and elevates treatment response in hepatocellular carcinoma
title_fullStr Targeting TROY-mediated P85a/AKT/TBX3 signaling attenuates tumor stemness and elevates treatment response in hepatocellular carcinoma
title_full_unstemmed Targeting TROY-mediated P85a/AKT/TBX3 signaling attenuates tumor stemness and elevates treatment response in hepatocellular carcinoma
title_short Targeting TROY-mediated P85a/AKT/TBX3 signaling attenuates tumor stemness and elevates treatment response in hepatocellular carcinoma
title_sort targeting troy-mediated p85a/akt/tbx3 signaling attenuates tumor stemness and elevates treatment response in hepatocellular carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131684/
https://www.ncbi.nlm.nih.gov/pubmed/35610614
http://dx.doi.org/10.1186/s13046-022-02401-6
work_keys_str_mv AT liubeilei targetingtroymediatedp85aakttbx3signalingattenuatestumorstemnessandelevatestreatmentresponseinhepatocellularcarcinoma
AT fangxiaona targetingtroymediatedp85aakttbx3signalingattenuatestumorstemnessandelevatestreatmentresponseinhepatocellularcarcinoma
AT kwongdoralaiwan targetingtroymediatedp85aakttbx3signalingattenuatestumorstemnessandelevatestreatmentresponseinhepatocellularcarcinoma
AT zhangyu targetingtroymediatedp85aakttbx3signalingattenuatestumorstemnessandelevatestreatmentresponseinhepatocellularcarcinoma
AT verhoeftkrista targetingtroymediatedp85aakttbx3signalingattenuatestumorstemnessandelevatestreatmentresponseinhepatocellularcarcinoma
AT gonglanqi targetingtroymediatedp85aakttbx3signalingattenuatestumorstemnessandelevatestreatmentresponseinhepatocellularcarcinoma
AT zhangbaifeng targetingtroymediatedp85aakttbx3signalingattenuatestumorstemnessandelevatestreatmentresponseinhepatocellularcarcinoma
AT chenjie targetingtroymediatedp85aakttbx3signalingattenuatestumorstemnessandelevatestreatmentresponseinhepatocellularcarcinoma
AT yuqianqian targetingtroymediatedp85aakttbx3signalingattenuatestumorstemnessandelevatestreatmentresponseinhepatocellularcarcinoma
AT luojie targetingtroymediatedp85aakttbx3signalingattenuatestumorstemnessandelevatestreatmentresponseinhepatocellularcarcinoma
AT tangying targetingtroymediatedp85aakttbx3signalingattenuatestumorstemnessandelevatestreatmentresponseinhepatocellularcarcinoma
AT huangtuxiong targetingtroymediatedp85aakttbx3signalingattenuatestumorstemnessandelevatestreatmentresponseinhepatocellularcarcinoma
AT lingfei targetingtroymediatedp85aakttbx3signalingattenuatestumorstemnessandelevatestreatmentresponseinhepatocellularcarcinoma
AT fuli targetingtroymediatedp85aakttbx3signalingattenuatestumorstemnessandelevatestreatmentresponseinhepatocellularcarcinoma
AT yanqian targetingtroymediatedp85aakttbx3signalingattenuatestumorstemnessandelevatestreatmentresponseinhepatocellularcarcinoma
AT guanxinyuan targetingtroymediatedp85aakttbx3signalingattenuatestumorstemnessandelevatestreatmentresponseinhepatocellularcarcinoma